# US 2025/0154256 A1 · Antibodies to programmed cell death protein 1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154256 A1
- Document ID: US20250154256A1
- Status: Published application
- Kind: A1
- Application number: 19/020,882
- Filed: 2025-01-14
- Published: 2025-05-15
- Earliest claimed: 2017-09-07
- Assignees: Augusta University Research Institute, Inc.
- Applicants: Augusta University Research Institute, Inc.
- Inventors: Samir Khleif; Mikayel Mkrtichyan
- Web page: https://patentgrep.com/patent/US20250154256A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1 and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation.

## Claims

### Claim 1

An antibody or antigen binding fragment thereof comprising heavy chain complementarity-determining regions (CDRs) having amino acid sequences according to SEQ ID NOs:6, 7, and 8, and light chain CDRs having amino acid sequences according to SEQ ID NOs:12, 13, and 14.

### Claim 2 (depends on 1)

The antibody or antigen binding fragment thereof of claim 1 comprising a heavy chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:4 or 5.

### Claim 3 (depends on 1, 2)

The antibody or antigen binding fragment thereof of claim 1 or 2 comprising a light chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:10 or 11.

### Claim 4

An antibody or antigen binding fragment thereof any comprising a heavy chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:4 or 5 and a light chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:10 or 11.

### Claim 5 (depends on 1, 2, 3, 4)

A transgenic animal engineered to express the antibody or antigen binding fragment thereof of any one of claims 1-4.

### Claim 6 (depends on 5)

The transgenic animal of claim 5, wherein the animal is a rodent.

### Claim 7 (depends on 6)

The transgenic animal of claim 6, wherein the rodent is a mouse.

### Claim 8

A nucleic acid encoding a heavy chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:4 or 5.

### Claim 9

A nucleic acid encoding a light chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:10 or 11.

### Claim 10

An antibody or antigen binding fragment thereof comprising heavy chain CDRs having amino acid sequences according to SEQ ID NOs:18, 19, and 20, and light chain CDRs having amino acid sequences according to SEQ ID NOs:24, 13, and 25.

### Claim 11 (depends on 10)

The antibody or antigen binding fragment thereof of claim 10 comprising a heavy chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:16 or 17.

### Claim 12 (depends on 10, 11)

The antibody or antigen binding fragment thereof of claim 10 or 11 comprising a light chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:22 or 23.

### Claim 13

An antibody or antigen binding fragment thereof comprising a heavy chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:16 or 17 and a light chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:22 or 23.

### Claim 14 (depends on 10, 11, 12, 13)

A transgenic animal engineered to express the antibody or antigen binding fragment thereof of any one of claims 10-13.

### Claim 15 (depends on 14)

The transgenic animal of claim 14, wherein the animal is a rodent.

### Claim 16 (depends on 15)

The transgenic animal of claim 15, wherein the rodent is a mouse.

### Claim 17

A nucleic acid encoding a heavy chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:16 or 17.

### Claim 18

A nucleic acid encoding a light chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:22 or 23.

### Claim 19

An antibody or antigen binding fragment thereof comprising heavy chain CDRs having amino acid sequences according to SEQ ID NOs:29, 30, and 31, and light chain CDRs having amino acid sequences according to SEQ ID NOs:35, 36, and 37.

### Claim 20 (depends on 19)

The antibody or antigen binding fragment thereof of claim 19 comprising a heavy chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:27 or 28.

### Claim 21 (depends on 19, 20)

The antibody or antigen binding fragment thereof of claim 19 or 20 comprising a light chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:33 or 34.

### Claim 22

An antibody or antigen binding fragment thereof comprising a heavy chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:27 or 28 and a light chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:33 or 34.

### Claim 23 (depends on 19, 20, 21, 22)

A transgenic animal engineered to express the antibody or antigen binding fragment thereof of any one of claims 19-22.

### Claim 24 (depends on 23)

The transgenic animal of claim 23, wherein the animal is a rodent.

### Claim 25 (depends on 24)

The transgenic animal of claim 24, wherein the rodent is a mouse.

### Claim 26

A nucleic acid encoding a heavy chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:27 or 28.

### Claim 27

A nucleic acid encoding a light chain with at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:33 or 34.

### Claim 28 (depends on 1, 2, 3, 4, 10, 11, 12, 13)

The antibody or antigen binding fragment thereof of any one of claim 1-4, 10-13, or 19-22, wherein the antibody or antigen binding fragment thereof is human, mouse, chimeric, humanized, monoclonal, bispecific, trispecific or multispecific.

### Claim 29

An antibody, or antigen binding fragment thereof comprising three light chain CDRs with amino acid sequences that are selected from the group consisting of SEQ ID NOs: 12, 13, 14, 24, 25, 35, 36, or 37.

### Claim 30

An antibody, or antigen binding fragment thereof comprising three heavy chain CDRs with amino acid sequences that are selected from the group consisting of SEQ ID NOs: 6, 7, 8, 18, 19, 20, 29, 30, or 31.

### Claim 31

An antibody, or antigen binding fragment thereof comprising three light chain CDRs with amino acid sequences that are selected from the group consisting of SEQ ID NOs: 12, 13, 14, 24, 25, 35, 36, or 37, and three heavy chain CDRs with amino acid sequences that are selected from the group consisting of SEQ ID NOs: 6, 7, 8, 18, 19, 20, 29, 30, or 31.

### Claim 32

An antibody or epitope binding fragment thereof or a fusion protein that immunospecifically binds to SEQ ID NO:38.

### Claim 33 (depends on 32)

The antibody or epitope binding fragment thereof or fusion protein of claim 32, wherein the immune cell is a T cell.

### Claim 34 (depends on 33)

The antibody or epitope binding fragment thereof or fusion protein of claim 33, wherein the T cell is a CD8+ T cell.

### Claim 35 (depends on 32)

The antibody or epitope binding fragment thereof or fusion protein of claim 32, wherein the antibody or antigen binding fragment thereof or fusion protein binds PD-1.

### Claim 36

An antibody or epitope binding fragment thereof or a fusion protein that immunospecifically binds to SEQ ID NO:38 on PD-1 expressed on the surface of an immune cell and induces or promotes a signal through PD-1 that activates or stimulates the immune cell.

### Claim 37 (depends on 1, 2, 3, 4, 10, 11, 12, 13, 19, 20, 21, 22, 29, 30, 31, 32, 33, 34, 35, 36)

A pharmaceutical composition comprising the antibody or antigen binding fragment thereof according to any one of claims 1-4, 10-13, 19-22 or 29-36.

### Claim 38 (depends on 37)

The pharmaceutical composition of claim 37, further comprising a second therapeutic agent.

### Claim 39 (depends on 37, 38)

The pharmaceutical composition of claim 37 or 38, further comprising a pharmaceutically acceptable excipient.

### Claim 40 (depends on 38)

The pharmaceutical composition of claim 38, wherein the second therapeutic agent comprises cyclophosphamide.

### Claim 41 (depends on 1, 2, 3, 4, 10, 11, 12, 13, 19, 20, 21, 22, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method of inducing, promoting, or enhancing an immune response in a subject in need thereof comprising:
administering to the subject an effective amount of an antibody or antigen binding fragment of any one of claims 1-4, 10-13, 19-22 or 29-36, or the pharmaceutical composition of any one of claims 37-40 to induce, promote, or enhance an immune response in the subject.

### Claim 42 (depends on 1, 2, 3, 4, 10, 11, 12, 13, 19, 20, 21, 22, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method for treating cancer in a subject in need thereof, comprising:
administering to the subject an effective amount of an antibody or antigen binding fragment of any one of claims 1-4, 10-13, 19-22 or 29-36, or the pharmaceutical composition of any one of claims 37-40 to treat cancer in the subject.

### Claim 43 (depends on 1, 2, 3, 4, 10, 11, 12, 13, 19, 20, 21, 22, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method for reducing tumor burden in a subject in need thereof, comprising:
administering to the subject an effective amount of an antibody or antigen binding fragment of any one of claims 1-4, 10-13, 19-22 or 29-36, or the pharmaceutical composition of any one of claims 37-40 to reduce tumor burden in the subject.

### Claim 44 (depends on 1, 2, 3, 4, 10, 11, 12, 13, 19, 20, 21, 22, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method for treating an infection in a subject in need thereof, comprising:
administering to the subject an effective amount of an antibody or antigen binding fragment of any one of claims 1-4, 10-13, 19-22 or 29-36, or the pharmaceutical composition of any one of claims 37-40 to treat the infection in the subject.
